In 2002 the first increase in sexually transmitted acute hepatitis C (HCV) was observed among human immunodeficiency virus (HIV)-positive men who have sex with men (MSM) in London. 1 Subsequently, outbreaks of acute HCV have been described globally in Asia, Australia, Canada and the USA and in almost all major cities from Western Europe but more recently also from Central and Eastern Europe. 2, 3 Most likely transmission risk factors are traumatic sex practices with increased risk for blood-blood contacts, concomitant other sexually transmitted diseases and use of Chemsex. 4, 5 Moreover, rectal shedding of HCV in HIV-coinfected MSM and transmission of HCV from dendritic cells have been discussed as contributors to the spread of acute HCV. 6, 7 Behavioral interventions in combination with increased roll-out of direct-acting antiviral (DAA) therapy have been discussed as a potential strategy to stop the ongoing HCV epidemic in this particular patient group. 8 In the current issue of the United European Gastroenterology Journal, Chromy and colleagues report on the outcome of DAA therapy in HIV-coinfected patients with acute HCV from Austria.
9 Reassuringly, they can confirm 100% cure rates following DAA therapy in early HCV infection. So clearly, early treatment intervention by preventing further HCV transmissions could be very instrumental in helping to achieve microelimination in this group. At least three countries have now reported a dramatic reduction in new incident cases of acute HCV following identification of HIV-positive MSM and ongoing HCV replication after acute HCV infection.
10-12 Delay of DAA therapy because of missing reimbursement for DAA therapy during acute HCV infection remains a challenge in Europe despite first cost-effectiveness studies demonstrating a cost benefit for early intervention rather than waiting six months to establish chronic HCV infection. 13 As shown in the paper by Chromy et al., 9 the probability of spontaneous HCV clearance is low at only 11%, making waiting an unattractive option. Similar data are reported from the European PROBE-C cohort, in which, in a much larger cohort, a 15% spontaneous HCV clearance rate was found in HIV-coinfected individuals with an episode of acute HCV.
14 Indeed, the current European AIDS Clinical Society treatment algorithm for management of acute HCV recommends a second quantitative HCV-RNA determination four weeks after initial diagnosis; in case there is no two log drop in HCV-RNA at this time, chronification of HCV infection can be expected and early DAA therapy is suggested. 15 Most studies seem to suggest that shorter treatment durations needed for treatment in early chronic HCV infections such as eight weeks of sofosbuvir/ledipasvir or grazoprevir/elbasvir are sufficient, which also implies cost savings toward treatment at later stages with more advanced fibrosis. 16, 17 The spread of HCV to HIVnegative MSM, particularly in preexposure prophylaxis cohorts, as well as the high reinfection rate among HIV-coinfected MSM with an acute HCV episode further enhance the need for early treatment intervention to prevent further spread of this epidemic. 5, 18 Clearly, it is no longer a question of treatment efficacy but rather treating all individuals identified with acute HCV to prevent further its spread and to contribute toward microelimination of HCV in this particular patient population. 
